Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
PURPOSE: Anhedonia is a core symptom of major depressive disorder (MDD), which has important functional consequences for the patient. This post hoc analysis investigated the relationship between anhedonia and functioning in patients with MDD treated with vortioxetine. PATIENTS AND METHODS: We conducted a pooled analysis of all 11 short-term, double-blind, randomized, placebo-controlled studies of vortioxetine (fixed dose, 5-20 mg/day) in patients with MDD which included Montgomery-Åsberg Depression Rating Scale (MADRS) and Sheehan Disability Scale (SDS) assessments. A short-term, randomized, active-controlled trial of flexible-dose treatment with vortioxetine (10-20 mg/day) versus agomelatine (25-50 mg/day) was also analyzed. Mean changes from baseline to study endpoint in MADRS total, MADRS anhedonia subscale, SDS total, and SDS social-functioning scores were analyzed by a mixed model for repeated measures. The relationship between treatment effects on anhedonia and functioning was investigated using path analysis. RESULTS: A total of 4988 patients with MDD were included in the placebo-controlled studies and 495 in the active-comparator study. Significant dose-dependent improvements in overall depressive symptoms, anhedonia, and measures of functioning were seen in vortioxetine-treated patients compared with those who received placebo or agomelatine. Results of the path analysis for the placebo-controlled studies suggested that the effect on functioning was mostly driven by the effect of treatment on MADRS anhedonia factors. CONCLUSION: Vortioxetine showed significant short-term efficacy against anhedonia in this large population of patients with MDD. In the placebo-controlled studies, improvements in functioning associated with vortioxetine appeared to be mostly driven by the effect of treatment on MADRS anhedonia factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The mesolimbic dopamine reward circuit in depression
Nestler, E. J., & Carlezon, W. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.018 · Cited by 2,059
A scale for the assessment of hedonic tone the Snaith-Hamilton pleasure scale
Snaith, R. P., Hamilton, M., Morley, S., Humayan, A., Hargreaves, D., & Trigwell, P. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.167.1.99 · Cited by 1,778
Sheehan, D. V., Harnett-Sheehan, K., & Raj, B. A. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199606003-00015 · Cited by 1,440
Scales for physical and social anhedonia.
Chapman, L. J., Chapman, J. P., & Raulin, M. L. (1976) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.85.4.374 · Cited by 1,234
Dopamine system dysregulation in major depressive disorders
Belujon, P., & Grace, A. A. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx056 · Cited by 754
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
Assessing anhedonia in depression: potentials and pitfalls
Rizvi, S. J., Pizzagalli, D. A., Sproule, B. A., & Kennedy, S. H. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.03.004 · Cited by 571
Sanchez, C., Asin, K. E., & Artigas, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.001 · Cited by 547
McMakin, D. L., Olino, T. M., Porta, G., Dietz, L. J., Emslie, G., Clarke, G., Wagner, K. D., Asarnow, J. R., Ryan, N. D., Birmaher, B., et al. (2012) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2012.01.011 · Cited by 448
Uher, R., Perlis, R. H., Henigsberg, N., Zobel, A., Rietschel, M., Mors, O., Hauser, J., Dernovsek, M. Z., Souery, D., Bajs, M., et al. (2012) · Psychological Medicine · doi:10.1017/s0033291711001905 · Cited by 420
Cited by
Nogo, D., Jasrai, A. K., Kim, H., Nasri, F., Ceban, F., Lui, L. M. W., Rosenblat, J. D., Vinberg, M., Ho, R., & McIntyre, R. S. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06105-9 · Cited by 54
Self-citationChristensen, M. C., Fagiolini, A., Florea, I., Loft, H., Cuomo, A., & Goodwin, G. M. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.07.099 · Cited by 52
Self-citationZheng, W., Gu, L.-M., Zhou, Y.-L., Wang, C.-Y., Lan, X.-F., Zhang, B., Shi, H.-S., Wang, D.-F., & Ning, Y.-P. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.780975 · Cited by 12
Zheng, W., Yang, X.-H., Gu, L.-M., Tan, J.-Q., Zhou, Y.-L., Wang, C.-Y., & Ning, Y.-P. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.06.081 · Cited by 11
Kato, M., Kikuchi, T., Watanabe, K., Sumiyoshi, T., Moriguchi, Y., Åström, D., & Christensen, M. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s428443 · Cited by 3
“38,39 Just as there is a phenotypic overlap between emotional blunting and anhedonia, there is overlap between the 4 MADRS items identified as important for emotional blunting and those included in the MADRS anhedonia factor score.”
BackgroundSelf-citation
Metadata
- Authors
- McIntyre, R. S., Loft, H., & Christensen, M. C.
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2021-02
- Volume
- Volume 17
- Pages
- 575-585
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- OpenAlex
- W3129382822
- Cited by
- 84
- References
- 43
- FWCI
- 6.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder. https://app.cochat.ai/papers/10.2147/ndt.s296451
- The paper
- McIntyre, R. S., Loft, H., & Christensen, M. C. (2021). Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/ndt.s296451
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.